Performance of the Roche cobas MTB assay for the molecular diagnosis of pulmonary tuberculosis in a high HIV burden setting

There is a need to increase access to and improve sensitivities of methods for diagnosing Mycobacterium tuberculosis infection and for detecting rifampicin and isoniazid resistance. The performance of the new cobas MTB assay for use on cobas 6800/8800 Systems (Roche) was assessed in this study and compared to two other commercial assays: Real-Time MTB (Abbott), and Xpert MTB/RIF (Cepheid).Molecular PCR-based assays were conducted on sputum specimens collected from individuals with presumptive and confirmed TB (n=294) from two clinical facilities in South Africa from December 2016 to October 2017.
Source: Journal of Molecular Diagnostics - Category: Pathology Authors: Tags: Regular Article Source Type: research